#	Pagina
attuale pagina	/open-h2020/projects/200812/index.html
-1	/open-h2020/projects/201330/index.html
-2	/open-h2020/projects/224716/index.html
-3	/open-h2020/projects/201214/index.html
-4	/open-consip/fornitori/2016/profilo-01643410366/index.html
-5	/open-h2020/projects/209224/index.html
-6	/open-h2020/projects/222912/index.html
-7	/open-h2020/projects/201632/index.html
-8	/open-h2020/projects/200830/index.html
-9	/open-h2020/projects/200312/index.html
-10	/open-h2020/projects/200097/index.html

Opendata, web and dolomites

NoCanTher SIGNED

Nanomedicine upscaling for early clinical phases of multimodal cancer therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Outcomes and
results

NoCanTher project word cloud

Explore the words cloud of the NoCanTher project. It provides you a very rough idea of what is the project "NoCanTher" about.

france validated device nocanther iron formulations assays efficacy participation nanoformulations csa uk ep2015 multifunctional sufficient align treatment sectors therapeutic breast chemical cancers scaling pancreatic run nanotherapeutic translating ireland intracellular carry nanoparticles combination candidates manufacturing investigational strategy timeline concentrate pct academia ordm plan preparation multigram dossier safety fp7 line nanoformulation certified imdd models generate patent certfified proven n mnp nanomedicine germany quality mentioned regulatory cancer 2019 efforts synergistic oxide drug 11 laboratory preclinical 262943 clinical designed amended effect countries milligram hyperthermia toxicicty vitro synthesis status peptide stages vivo spain anticancer successfully medicinal industry 056631 bare filed therapy magnetic multifuntionalised protocol multifun group authorisation material july preceding

Project "NoCanTher" data sheet

The following table provides information about the project.

Coordinator	FUNDACION IMDEA NANOCIENCIA Organization address address: CIUDAD UNIVERSITARIA DE CANTOBLANCO - CALLE FARADAY 9 city: MADRID postcode: 28049 website: http://www.nanociencia.imdea.org/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	http://www.nocanther-project.eu/
Total cost	7˙113˙778 €
EC max contribution	7˙113˙778 € (100%)
Programme	1. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
Code Call	H2020-NMP-2015-two-stage
Funding Scheme	RIA
Starting year	2016
Duration (year-month-day)	from 2016-04-01 to 2021-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	FUNDACION IMDEA NANOCIENCIA FUNDACION IMDEA NANOCIENCIA Organization address address: CIUDAD UNIVERSITARIA DE CANTOBLANCO - CALLE FARADAY 9 city: MADRID postcode: 28049 website: http://www.nanociencia.imdea.org/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (MADRID)	coordinator	729˙696.00
2	BIOKERALTY RESEARCH INSTITUTE AIE BIOKERALTY RESEARCH INSTITUTE AIE Organization address address: ENTIDAD ARCAUTE, 005, ARCAUTE city: ARCAUTE ALAVA postcode: 1192 website: www.grupo-praxis.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (ARCAUTE ALAVA)	participant	1˙494˙864.00
3	RESONANT CIRCUITS LIMITED RESONANT CIRCUITS LIMITED Organization address address: ALBERMALE STREET THE ROYAL 21 city: LONDON postcode: W1S 4BS website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	888˙684.00
4	Universitätsklinikum Jena Universitätsklinikum Jena Organization address address: Bachstraße 18 city: Jena postcode: 7743 website: www.uniklinikum-jena.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (Jena)	participant	755˙768.00
5	THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN Organization address address: College Green city: DUBLIN postcode: 2 website: www.tcd.ie contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (DUBLIN)	participant	671˙039.00
6	FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA Organization address address: PASSEIG VALL D HEBRON 119-129 EDIFICIO DE RECERCA city: BARCELONA postcode: 8035 website: http://www.vhir.org/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	630˙633.00
7	UNIVERSITE DE PARIS UNIVERSITE DE PARIS Organization address address: 85 BD SAINT GERMAIN city: PARIS postcode: 75006 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	603˙527.00
8	HOSPITAL UNIVERSITARIO DE FUENLABRADA HOSPITAL UNIVERSITARIO DE FUENLABRADA Organization address address: CALLE DEL MOLINO 2 city: FUENLABRADA postcode: 28942 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (FUENLABRADA)	participant	553˙624.00
9	FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON Organization address address: CALLE NAZARET 115-117 city: BARCELONA postcode: 8035 website: http://www.vhio.net contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	347˙979.00
10	IMMUPHARMA PLC IMMUPHARMA PLC Organization address address: 50 BROADWAY city: LONDON postcode: SW1H 0RG website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	175˙250.00
11	CHEMICELL GMBH CHEMICELL GMBH Organization address address: ERESBURGSTRASSE 22-23 city: BERLIN postcode: 12103 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BERLIN)	participant	174˙171.00
12	FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III Organization address address: CALLE MELCHOR FERNANDEZ ALMAGRO 3 city: MADRID postcode: 28029 website: www.cnio.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (MADRID)	participant	88˙538.00
13	UNIVERSITE PARIS DIDEROT - PARIS 7 UNIVERSITE PARIS DIDEROT - PARIS 7 Organization address address: RUE THOMAS MANN 5 city: PARIS postcode: 75205 website: www.univ-paris-diderot.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	0.00

Map

Project objective

This project has been amended in July 2019 to better align the described tasks and timeline with the current status of the project.

The preceding Multifun Consortium (FP7 project Nº. 262943) has developed and validated distinct nanoformulations as therapeutic approach against pancreatic and breast cancer. These nanoformulations are based on magnetic iron oxide nanoparticles (MNP) multifuntionalised with a target peptide and an anticancer chemical drug, allowing for a synergistic therapeutic effect produced by the combination of intracellular drug delivery and magnetic hyperthermia. In particular, some of the designed formulations (patent filed PCT/EP2015/056631) have proven their efficacy, safety and non-toxicicty, in in vitro and in vivo studies, against the mentioned cancers, thus making them promising candidates to produce a novel nanomedicine therapy for cancer.

NoCanTher aims at translating one of these nanoformulations to early clinical development for pancreatic cancer. Particularly, we plan to assess bare nanoparticles (System B) and multifunctional nanoparticles (System A) in advanced preclinical models and run a clinical study with the System B. To successfully reach this objective, we will concentrate our efforts in two main group of activities:

• Nanotherapeutic up-scaling under Certfified conditions: NoCanTher will scale up the manufacturing of the proposed nanoformulation from milligram-scale laboratory synthesis up to multigram-scale production to generate sufficient material for clinical and regulatory assays. To this aim, a certified production line will be optimised and the relevant quality control will be conducted at the different stages of the up-scaling process. • Clinical Study: NoCanTher will include late preclinical parameter testing to raise a clinical treatment protocol, regulatory assays, as well as the design of the clinical study and the preparation of the Investigational Medicinal Device Dossier (IMDD).

This strategy will allow us to apply for Clinical Study Authorisation (CSA) then, we will carry out a Clinical Study. NoCanTher involves the participation of 11 institutions from three different sectors (academia, industry, clinical) and from five different countries (Ireland, France, Germany, Spain and the UK).

Deliverables

List of deliverables.
Public Web Site and Project Presentation	Websites, patent fillings, videos etc.	2020-02-25 11:29:43

Take a look to the deliverables list in detail: detailed list of NoCanTher deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2017	Paul Southern, Quentin A. Pankhurst Commentary on the clinical and preclinical dosage limits of interstitially administered magnetic fluids for therapeutic hyperthermia based on current practice and efficacy models published pages: 671-686, ISSN: 0265-6736, DOI: 10.1080/02656736.2017.1365953	International Journal of Hyperthermia 34/6	2020-02-25
2017	Amanda K Silva, Alba Nicolas-Boluda, Laura Fouassier, Florence Gazeau Overcoming the tumor microenvironment: the role of nanohyperthermia published pages: 1213-1215, ISSN: 1743-5889, DOI: 10.2217/nnm-2017-0096	Nanomedicine 12/11	2020-02-25
2017	Sandra Hallasch, Sindy Frick, Maximilian Jung, Ingrid Hilger How gastrin-releasing peptide receptor (GRPR) and Î±vÎ²3 integrin expression reflect reorganization features of tumors after hyperthermia treatments published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-017-06100-7	Scientific Reports 7/1	2020-02-25
2017	Jelena Kolosnjaj-Tabi, Iris Marangon, Alba Nicolas-Boluda, Amanda K.A. Silva, Florence Gazeau Nanoparticle-based hyperthermia, a local treatment modulating the tumor extracellular matrix published pages: 123-137, ISSN: 1043-6618, DOI: 10.1016/j.phrs.2017.07.010	Pharmacological Research 126	2020-02-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOCANTHER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOCANTHER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.2.)

iNanoBIT (2017)

Integration of Nano- and Biotechnology for beta-cell and islet Transplantation

Read More

nTRACK (2017)

Multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration

Read More

NOBEL (2017)

Mobilising the European nano-biomedical ecosystem

Read More